What You Should Know:
– 23andMe Holding Co., a leading player in preventative health and therapeutics, and Nightingale Health, a pioneer in biomarker testing, announced a collaboration to pilot Nightingale’s blood metabolomics panel with a group of 23andMe members.
– This pilot program represents a significant step forward in personalized health assessment. By combining genetic and blood biomarker data, 23andMe and Nightingale Health are paving the way for a future where individuals can take a more proactive approach to managing their health and well-being.
Unlocking Deeper Health Insights
This pilot program offers a glimpse into the future of personalized health assessments. Here’s what it entails:
- Nightingale’s Remote Health Check: This innovative blood test measures dozens of biomarkers, including cholesterol, apolipoproteins, and fatty acids. These markers can provide valuable insights into disease risk and inform personalized health strategies.
- Enhanced Risk Prediction: The data from Nightingale’s blood panel will be integrated with 23andMe’s existing genetic testing. This combined approach has the potential to improve the accuracy of risk assessments for various health conditions.
- Actionable Insights: By combining genetic and blood biomarker data, 23andMe aims to empower users with more actionable insights. This can help individuals identify areas for improvement, such as diet or exercise adjustments, to optimize their health.
A Pilot Program for Personalized Health
As part of this initiative, 23andMe will offer up to 5,000 of its premium and total health members the opportunity to receive Nightingale’s Remote Health Check blood test free of charge. This pilot program will serve several purposes:
- Gather User Feedback: 23andMe will collect feedback from participants on their experience with blood testing, at-home sample collection, and the value of combining genetic and blood biomarker data.
- Evaluate Data Integration: The pilot will assess how effectively 23andMe can integrate Nightingale’s blood test data with its existing genetic testing platform.
“This collaboration enables a globally unique feature set for 23andMe’s consumer health services. Together, we can help customers track and improve their health with regular blood testing using Nightingale Health’s technology,” said Teemu Suna, CEO and Founder of Nightingale Health. “This marks an important step in the execution of Nightingale Health’s strategy, as it announces an important partnership providing access to the consumer health market.”
